Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
HRMY Stock Chart & Stats
$28.57
-$1.07(-3.04%)
At close: 4:00 PM EST
$28.57
-$1.07(-3.04%)
Day’s Range― - ―
52-Week Range$25.52 - $40.87
Previous CloseN/A
Volume87.33K
Average Volume (3M)1.05M
Market Cap
$1.65B
Enterprise Value$1.15B
Total Cash (Recent Filing)$775.34M
Total Debt (Recent Filing)$239.58M
Price to Earnings (P/E)13.6
Beta1.05
Next Earnings
May 05, 2026EPS Estimate
0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.38
Shares Outstanding57,840,614
10 Day Avg. Volume1,485,214
30 Day Avg. Volume1,054,177
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.47
Price to Sales (P/S)2.48
P/FCF Ratio6.18
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit1.72
Enterprise Value/Ebitda4.57
Forecast
1Y Price Target
$41.25Price Target Upside44.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)3.61
Revenue Forecast (FY)$1.01B
Bulls Say, Bears Say
Bulls Say
Commercial PerformanceAnalyst highlights sustained patient growth and repeated revenue gains for Wakix, signaling strong commercial momentum that supports expectations of scalable long-term sales.
Financial FlexibilityA strong cash position provides the company flexibility to fund internal pipeline programs and pursue business development opportunities without immediate reliance on external financing.
Pipeline Expansion And Label GrowthPlanned label expansion into pediatric cataplexy and development of a new pitolisant formulation for fatigue in neurological conditions broaden the addressable market and create additional commercialization pathways.
Bears Say
Commercial Concentration RiskReliance on a single meaningful commercial product leaves the company vulnerable to significant valuation pressure if Wakix exclusivity is eroded, given limited diversification of revenue sources.
Legal Overhang From LitigationAn unresolved patent challenger and ongoing litigation create a material overhang that could overturn settlements or accelerate generic entry, weighing on investor sentiment and future revenue visibility.
Profitability And Expense PressureRising operating expenses and weaker gross margins have led to earnings shortfalls that increase scrutiny on profitability and could prompt analysts to adopt more conservative financial assumptions.
Harmony Biosciences Holdings News
HRMY FAQ
What was Harmony Biosciences Holdings’s price range in the past 12 months?
Harmony Biosciences Holdings lowest stock price was $25.52 and its highest was $40.87 in the past 12 months.
What is Harmony Biosciences Holdings’s market cap?
Harmony Biosciences Holdings’s market cap is $1.65B.
When is Harmony Biosciences Holdings’s upcoming earnings report date?
Harmony Biosciences Holdings’s upcoming earnings report date is May 05, 2026 which is in 55 days.
How were Harmony Biosciences Holdings’s earnings last quarter?
Harmony Biosciences Holdings released its earnings results on Feb 24, 2026. The company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.876 by -$0.496.
Is Harmony Biosciences Holdings overvalued?
According to Wall Street analysts Harmony Biosciences Holdings’s price is currently Undervalued.
Does Harmony Biosciences Holdings pay dividends?
Harmony Biosciences Holdings does not currently pay dividends.
What is Harmony Biosciences Holdings’s EPS estimate?
Harmony Biosciences Holdings’s EPS estimate is 0.78.
How many shares outstanding does Harmony Biosciences Holdings have?
Harmony Biosciences Holdings has 57,840,614 shares outstanding.
What happened to Harmony Biosciences Holdings’s price movement after its last earnings report?
Harmony Biosciences Holdings reported an EPS of $0.38 in its last earnings report, missing expectations of $0.876. Following the earnings report the stock price went up 4.913%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings?
Currently, no hedge funds are holding shares in HRMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harmony Biosciences Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.25 (44.38% Upside)
$41.25 (44.38% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 229.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.14%
12-Months-Change
Fundamentals
Return on Equity
19.84%
Trailing 12-Months
Asset Growth
27.26%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
HRMY Company Deck
HRMY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong commercial execution and clear momentum: record quarterly revenues (+21% YoY), robust cash generation ($348.2M) and a healthy cash balance ($882.5M); sustained patient adds and a reiterated blockbuster revenue guide for 2026 support a positive commercial outlook. The company is actively advancing a rich late-stage pipeline (5 Phase III programs) with multiple near-term catalysts (pitolisant GR NDA Q2 2026, pitolisant HD top line 2027, EPX-100 data H1 2027). Key challenges include a significant rise in operating expenses (~45% YoY), a near‑term drop in non-GAAP adjusted net income and EPS (~48% decline), ongoing ANDA litigation/IP uncertainty (one filer unresolved), and competitive/enrollment pressures in certain programs. Overall, achievements and forward-looking catalysts materially outweigh the risks, though litigation and elevated investment-driven expenses warrant monitoring.View all HRMY earnings summariesHRMY Stock 12 Month Forecast
Average Price Target
$41.25
▲(44.38% Upside)
Technical Analysis
Ownership Overview
1.07% Insiders
20.34% Mutual Funds
10.29% Other Institutional Investors
41.38% Public Companies and Individual Investors